Rajesh Kumar
Stock Analyst at HSBC
(2.82)
# 1,896
Out of 5,072 analysts
27
Total ratings
52.94%
Success rate
7.76%
Average return
Main Sectors:
Stocks Rated by Rajesh Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Downgrades: Hold | n/a | $48.71 | - | 3 | Nov 24, 2025 | |
| IQV IQVIA Holdings | Upgrades: Buy | $195 → $235 | $231.80 | +1.38% | 2 | Oct 9, 2025 | |
| ABBV AbbVie | Downgrades: Hold | n/a | $227.66 | - | 4 | Oct 1, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Hold | $675 → $700 | $1,104.34 | -36.61% | 3 | Aug 27, 2025 | |
| KDP Keurig Dr Pepper | Upgrades: Buy | $36 → $42 | $27.68 | +51.73% | 1 | Apr 25, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $660 → $670 | $593.25 | +12.94% | 3 | Apr 30, 2024 | |
| DHR Danaher | Upgrades: Buy | $250 → $280 | $228.46 | +22.56% | 2 | Apr 17, 2024 | |
| UNH UnitedHealth Group | Upgrades: Hold | $460 | $329.71 | +39.52% | 2 | Apr 4, 2024 | |
| TEVA Teva Pharmaceutical Industries | Initiates: Buy | $13 | $26.32 | -50.61% | 1 | Dec 18, 2023 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Hold | $55 → $53 | $49.25 | +7.61% | 2 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Reduce | $97 | $25.01 | +287.84% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $124 | $102.70 | +20.74% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $25.71 | +94.48% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $123 | $104.63 | +17.56% | 1 | Jul 14, 2023 |
Novo Nordisk
Nov 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $48.71
Upside: -
IQVIA Holdings
Oct 9, 2025
Upgrades: Buy
Price Target: $195 → $235
Current: $231.80
Upside: +1.38%
AbbVie
Oct 1, 2025
Downgrades: Hold
Price Target: n/a
Current: $227.66
Upside: -
Eli Lilly and Company
Aug 27, 2025
Upgrades: Hold
Price Target: $675 → $700
Current: $1,104.34
Upside: -36.61%
Keurig Dr Pepper
Apr 25, 2025
Upgrades: Buy
Price Target: $36 → $42
Current: $27.68
Upside: +51.73%
Thermo Fisher Scientific
Apr 30, 2024
Maintains: Buy
Price Target: $660 → $670
Current: $593.25
Upside: +12.94%
Danaher
Apr 17, 2024
Upgrades: Buy
Price Target: $250 → $280
Current: $228.46
Upside: +22.56%
UnitedHealth Group
Apr 4, 2024
Upgrades: Hold
Price Target: $460
Current: $329.71
Upside: +39.52%
Teva Pharmaceutical Industries
Dec 18, 2023
Initiates: Buy
Price Target: $13
Current: $26.32
Upside: -50.61%
Bristol-Myers Squibb Company
Oct 27, 2023
Upgrades: Hold
Price Target: $55 → $53
Current: $49.25
Upside: +7.61%
Jul 14, 2023
Initiates: Reduce
Price Target: $97
Current: $25.01
Upside: +287.84%
Jul 14, 2023
Initiates: Buy
Price Target: $124
Current: $102.70
Upside: +20.74%
Jul 14, 2023
Initiates: Buy
Price Target: $50
Current: $25.71
Upside: +94.48%
Jul 14, 2023
Initiates: Hold
Price Target: $123
Current: $104.63
Upside: +17.56%